Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ephicol is a multi-ingredient oral capsule manufactured by Regal Pharmaceuticals, a generic pharmaceutical company based in Kenya. It is formulated as a cold and flu remedy containing four active ingredients: paracetamol (500 mg), caffeine anhydrous (30 mg), phenylephrine hydrochloride (5 mg), and chlorpheniramine maleate (2 mg). Paracetamol serves as an analgesic and antipyretic, while caffeine acts as a stimulant that potentiates the pain-relieving effects. Phenylephrine hydrochloride functions as a decongestant to reduce nasal swelling, and chlorpheniramine maleate is an antihistamine that alleviates allergic symptoms such as sneezing and watery eyes. The product is indicated for the symptomatic relief of the common cold, influenza, and associated allergic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ephicol.